TRCT
GRCE

Tower Research Capital (TRC)’s Grace Therapeutics GRCE Stock Holding History

Tower Research Capital (TRC)’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.75K Buy
1,652
+1,237
+298% +$3.42K ﹤0.01% 4479
2026
Q1 		$1.92K Sell
415
-1,530
-79% -$6.01K ﹤0.01% 4577
2025
Q4 		$6.73K Buy
1,945
+335
+21% +$1.06K ﹤0.01% 4052
2025
Q3 		$4.79K Buy
1,610
+259
+19% +$812 ﹤0.01% 4296
2025
Q2 		$4.01K Sell
1,351
-2,078
-61% -$5.53K ﹤0.01% 4396
2025
Q1 		$7.82K Buy
3,429
+1,932
+129% +$6.09K ﹤0.01% 3931
2024
Q4 		$5.6K Sell
1,497
-1,235
-45% -$4.23K ﹤0.01% 4267
2024
Q3 		$8.2K Buy
+2,732
New +$7.3K ﹤0.01% 3976
2022
Q2 		– Sell
-102
Closed -$1K – 6607
2022
Q1 		$1K Buy
102
+45
+79% +$321 ﹤0.01% 5871
2021
Q4 		$0 Buy
57
+25
+78% +$226 ﹤0.01% 6652
2021
Q3 		$0 Buy
+32
New +$630 ﹤0.01% 6256
2017
Q2 		– Sell
-5
Closed – – 3557
2017
Q1 		$0 Sell
5
-1
-17% -$61 ﹤0.01% 4041
2016
Q4 		$1K Sell
6
-7
-54% -$470 ﹤0.01% 3673
2016
Q3 		$1K Buy
13
+5
+63% +$370 ﹤0.01% 3391
2016
Q2 		$1K Sell
8
-5
-38% -$340 ﹤0.01% 4235
2016
Q1 		$1K Buy
13
+9
+225% +$705 ﹤0.01% 3818
2015
Q4 		$1K Buy
+4
New +$472 ﹤0.01% 4191
2013
Q3 		– Sell
-3
Closed -$4K – 4897
2013
Q2 		$4K Buy
+3
New +$3.61K ﹤0.01% 3134

Other funds holding GRCE

Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.23B AUM 74.49% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Tower Research Capital (TRC)'s GRCE Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Grace Therapeutics (GRCE) stake by 298% in Q2 2026, buying an estimated $3.42K and bringing the position to 1,652 shares worth $3.75K. The position accounts for ﹤0.01% of the portfolio, ranked #4479.

Tower Research Capital (TRC) first reported a position in GRCE in Q2 2013 and has held it in 18 quarters since. The position peaked at $8.2K in Q3 2024. 31 funds tracked by Wall St. Rank hold GRCE as of Q2 2026.

  • Tower Research Capital (TRC) held 1,652 shares of Grace Therapeutics worth $3.75K as of Q2 2026.
  • Tower Research Capital (TRC) bought 1,237 Grace Therapeutics shares in Q2 2026, an estimated $3.42K.
  • Grace Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4479 holding.
  • Tower Research Capital (TRC) first reported a position in Grace Therapeutics in Q2 2013 and has held it in 18 quarters since.
  • Tower Research Capital (TRC)'s Grace Therapeutics position peaked at $8.2K in Q3 2024.
  • 31 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.